𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Adaptimmune's CEO Adrian (Ad) Rawcliffe discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma. He describes how the treatment works, the expected rollout and cost, and what this means for TCR therapies going forward. Full video: https://lnkd.in/gCBVGzpd BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Jefferies' SVP Andrew Tsai joins BiotechTV for Analyst Thursdays and talks neuro names and more. He shares his take on biotech and discusses Verona, Rapport, Atai Life Sciences, Intra-Cellular, Alto Neuro, Athira, and Relmada. Full video: https://lnkd.in/guR3Q_59 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today. Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for neurofibromatosis Type 1 into a phase 2 study. Full video: https://lnkd.in/gZFRqcFf BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: io9, Inc. published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides. CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the treatable patient population, and next steps towards applying for approval as a companion diagnostic for PARP inhibitors. Full video: https://lnkd.in/g-6Rp3bT BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Autobahn Therapeutics, Inc. announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression. CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry platform. Plus, how the funding will also allow the company to advance a S1P receptor modulator. Full video: https://lnkd.in/gdCkzhS7 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Bessemer Venture Partners' Morgan Cheatham shares his take on AI in life sciences. He talks about the two different categories of companies based on their use of AI, and discusses what he looks for when evaluating them. Full video: https://lnkd.in/gNDG-yVV BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Generate:Biomedicines' CEO Michael Nally gives an update on the company's clinical and emerging programs. He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more. Full video: https://lnkd.in/gPFP2yEK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies. He explains how the goal of Eigen is to help up-regulate antigens of interest and how technologies today allow a smaller startup to derive and test large datasets. Full video: https://lnkd.in/g55Jh67m BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: The Co-Hosts of the AI x Bio Summit at NYSE talk about the conference and their take on AI. NYSE's Eric J. Dimise, PhD and Decoding Bio's Amee Kapadia describe the ways that AI is already impacting healthcare today and where it might be headed in the future. Full video: https://lnkd.in/gtm3jMRi BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent